InSilico Medicine Hong Kong Limited

Insilico Medicine developed an AI platform which allows for rapid identification of new molecular targets using multi-omics data and rapid generation of novel compounds using AI. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Technology Innovation Award. The company is betting on the innovative pharmaceutical industry in Greater China and established the HQ in Hong Kong and R&D offices in Taipei. It has a close collabo